
Strides Pharma Science Ltd
NSE:STAR

Strides Pharma Science Ltd
Gross Profit
Strides Pharma Science Ltd
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
Strides Pharma Science Ltd
NSE:STAR
|
Gross Profit
â‚ą27.1B
|
CAGR 3-Years
18%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
![]() |
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Gross Profit
â‚ą220.1B
|
CAGR 3-Years
17%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
![]() |
Cipla Ltd
NSE:CIPLA
|
Gross Profit
â‚ą181.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
10%
|
|
![]() |
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Gross Profit
â‚ą411.1B
|
CAGR 3-Years
14%
|
CAGR 5-Years
12%
|
CAGR 10-Years
8%
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Gross Profit
â‚ą85.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Gross Profit
â‚ą69.4B
|
CAGR 3-Years
17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Strides Pharma Science Ltd
Glance View
Strides Pharma Science Ltd. engages in the development, manufacture and distribution of Internet Protocol-led generics and bio-pharmaceutical products. The company is headquartered in Bangalore, Karnataka. The company went IPO on 2000-02-03. The firm is focused on development and manufacture of IP-led niche and pharmaceutical products. The company operates through two segments: Pharmaceutical and Bio-pharmaceutical. Its geographical segment includes Africa, Australia, Asia (excluding India), North America, Europe, India, and Others. The firm manufactures a range of niche and pharmaceutical products, including a range of dosage forms such as, liquids, creams and ointments, soft gels, sachets, tablets, and modified release dosage formats. The company has eight manufacturing units located in India (Bengaluru-two sites, Puducherry, and Chennai), Singapore, Italy (Milan), the United States (Florida) and Kenya (Nairobi). The company is also engaged in manufacturing soft gelatin capsules. The company develops and manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drug segments for its institutional business.

See Also
What is Strides Pharma Science Ltd's Gross Profit?
Gross Profit
27.1B
INR
Based on the financial report for Dec 31, 2024, Strides Pharma Science Ltd's Gross Profit amounts to 27.1B INR.
What is Strides Pharma Science Ltd's Gross Profit growth rate?
Gross Profit CAGR 5Y
11%
Over the last year, the Gross Profit growth was 16%. The average annual Gross Profit growth rates for Strides Pharma Science Ltd have been 18% over the past three years , 11% over the past five years .